AlflutinibAlternative Names: Alflutinib Mesylate; AST 2818
Latest Information Update: 01 Dec 2016
At a glance
- Originator Allist Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Epidermal growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 30 Nov 2016 Allist Pharmaceuticals plans a phase I trial for Non-small cell lung cancer in China (NCT02973763)